Activation of the TLR2 and TLR4 pathways by dentilisin leads to the upregulation of MyD88-dependent signaling, which triggers pro-inflammatory cytokines and excessive endothelial cell activation, contributing to endothelial dysfunction and CVD pathogenesis. The gene discussed is TLR4; the disease is endothelial dysfunction.